🔗 Share this article Individuals Discontinuing Anti-Obesity Injections Regain Pounds Four Times Faster Compared to Those on Conventional Diets Obesity treatment often requires ongoing approaches. New research reveals that people who stop using new weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who halt traditional diet and exercise plans. Published data in a major medical journal shows that while overweight individuals can lose substantial amounts of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping. "People using these drugs must be aware of the potential of rapid weight regain when the medication ends," stated researcher Dr. Susan Jebb. That rate of recovery means a reversion to starting mass in about 18 months. Weighing Approaches The study, which examined 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with other pills. Scientists note that people who lose weight through dieting typically have a slower creep back—approximately 100 grams monthly—post-intervention. Understanding the Fast Regain Nutrition scientists believe the mode of action of the drugs is key to understanding the amplified rebound. These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness. "Long-term administration of GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher. "Withdrawal of this hormone supplement means hunger is uncontrolled, making overeating far more likely." An Ongoing Issue? Health authorities advise the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications. Many experts contend that, due to the significant potential of weight regain, the therapy should be considered long-term. This view is echoed by pharmaceutical companies, who note that the findings "underscore the long-term character of excess weight," comparing it to managing conditions like hypertension. Patient Testimonies People who have stopped the jabs report a intense resurgence of cravings. "It felt as if a trigger flipping and you become extremely hungry," recalled a patient. The struggle is worsened if patients have not developed lasting lifestyle or habit modifications during therapy. Widespread Use Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow. Use is higher among women than males. The 40s and 50s demographic shows the greatest level of interest. A large proportion access the drugs through private healthcare rather than the NHS. Finally, researchers emphasize that while these medications are powerful tools for shedding pounds, they are not a magic fix and maintained weight loss relies on combined behavioural support.
Obesity treatment often requires ongoing approaches. New research reveals that people who stop using new weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who halt traditional diet and exercise plans. Published data in a major medical journal shows that while overweight individuals can lose substantial amounts of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping. "People using these drugs must be aware of the potential of rapid weight regain when the medication ends," stated researcher Dr. Susan Jebb. That rate of recovery means a reversion to starting mass in about 18 months. Weighing Approaches The study, which examined 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with other pills. Scientists note that people who lose weight through dieting typically have a slower creep back—approximately 100 grams monthly—post-intervention. Understanding the Fast Regain Nutrition scientists believe the mode of action of the drugs is key to understanding the amplified rebound. These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness. "Long-term administration of GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher. "Withdrawal of this hormone supplement means hunger is uncontrolled, making overeating far more likely." An Ongoing Issue? Health authorities advise the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications. Many experts contend that, due to the significant potential of weight regain, the therapy should be considered long-term. This view is echoed by pharmaceutical companies, who note that the findings "underscore the long-term character of excess weight," comparing it to managing conditions like hypertension. Patient Testimonies People who have stopped the jabs report a intense resurgence of cravings. "It felt as if a trigger flipping and you become extremely hungry," recalled a patient. The struggle is worsened if patients have not developed lasting lifestyle or habit modifications during therapy. Widespread Use Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow. Use is higher among women than males. The 40s and 50s demographic shows the greatest level of interest. A large proportion access the drugs through private healthcare rather than the NHS. Finally, researchers emphasize that while these medications are powerful tools for shedding pounds, they are not a magic fix and maintained weight loss relies on combined behavioural support.